

Abstract

The present invention provides a novel isoindolinone derivative compound, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, as caspase inhibitors. The novel isoindolinone derivative compound of the present invention was confirmed to exhibit
5 an excellent interleukin-1 β (IL-1 β) reducing effect and an excellent apoptosis-reducing effect, thus exhibiting excellent activity as a caspase inhibitor, and thus, it has been found that the novel isoindolinone derivative compound can be used for the prevention or treatment of caspase-related diseases.

Therefore, the novel isoindolinone derivative compound of the present invention can
10 be effectively used in the prevention or treatment of caspase-related diseases in the medical and pharmaceutical fields.